PMID- 35219639 OWN - NLM STAT- MEDLINE DCOM- 20220429 LR - 20220429 IS - 1096-0333 (Electronic) IS - 0041-008X (Linking) VI - 440 DP - 2022 Apr 1 TI - Cadmium induces placental glucocorticoid barrier damage by suppressing the cAMP/PKA/Sp1 pathway and the protective role of taurine. PG - 115938 LID - S0041-008X(22)00083-7 [pii] LID - 10.1016/j.taap.2022.115938 [doi] AB - Cadmium (Cd) exposure during pregnancy damages the placental glucocorticoid (GC) barrier, exposes the foetus to excess corticosterone (CORT) levels, and eventually inhibits foetal development. In addition, taurine (Tau) alleviates the toxicity of Cd on liver and kidney, but limited data are available on the role of Tau against the toxicity of heavy metals on female reproduction and fetal development. The present study was conducted to investigate the specific mechanism of Cd-induced placental GC barrier damage and the protective role of Tau. Pregnant rats were administered CdCl2 (1 mg/kg/day) and Tau (100, 200, or 300 mg/kg/day) by gavage from gestational day (GD) 0 to 19. The data showed that CdCl(2) increased the foetal growth restriction (FGR) rate of the offspring, and the levels of CORT in the placental, maternal and foetal serum. Treatment with Tau significantly reversed the impact of Cd on both maternal and fetal parameters. Additionally, Tau can attenuate Cd-induced inhibition of 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) and specificity protein 1 (Sp1) in vivo and vitro. Furthermore, Sp1-siRNA alone reduced 11beta-HSD2 levels and had a further inhibitory effect when the cells were treated with Cd simultaneously. Moreover, Cd suppressed cAMP/PKA signalling. Forskolin (adenylate cyclase agonist) pretreatment activated cAMP/PKA signalling and restored the Cd-induced downregulation of Sp1 and 11beta-HSD2. Tau alleviated the Cd-induced decrease of Sp1 via activating cAMP/PKA signalling. Therefore, the results highlight that Tau protects against Cd-induced impairments in GC barrier damage by upregulating the cAMP/PKA/Sp1 pathway in placental trophoblasts. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Chen, Na AU - Chen N AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. FAU - Tong, Xia AU - Tong X AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. FAU - Wu, Sisi AU - Wu S AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. FAU - Xu, Xu AU - Xu X AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. FAU - Chen, Qihui AU - Chen Q AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. FAU - Wang, Fan AU - Wang F AD - Department of Obstetrics and Gynaecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China; The Second Clinical Medical College of Wenzhou Medical University, Wenzhou City, Zhejiang Province 325000, China. Electronic address: wf@wzhealth.com. LA - eng PT - Journal Article DEP - 20220224 PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Glucocorticoids) RN - 00BH33GNGH (Cadmium) RN - 1EQV5MLY3D (Taurine) RN - EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 2) RN - W980KJ009P (Corticosterone) SB - IM MH - *11-beta-Hydroxysteroid Dehydrogenase Type 2/metabolism MH - Animals MH - Cadmium/metabolism MH - Corticosterone MH - Female MH - Glucocorticoids/metabolism/pharmacology MH - *Placenta/metabolism MH - Pregnancy MH - Rats MH - Taurine/pharmacology OTO - NOTNLM OT - 11beta-HSD2 OT - Cadmium OT - Glucocorticoids OT - Sp1 OT - Taurine EDAT- 2022/02/28 06:00 MHDA- 2022/04/30 06:00 CRDT- 2022/02/27 20:28 PHST- 2021/07/24 00:00 [received] PHST- 2022/02/17 00:00 [revised] PHST- 2022/02/18 00:00 [accepted] PHST- 2022/02/28 06:00 [pubmed] PHST- 2022/04/30 06:00 [medline] PHST- 2022/02/27 20:28 [entrez] AID - S0041-008X(22)00083-7 [pii] AID - 10.1016/j.taap.2022.115938 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2022 Apr 1;440:115938. doi: 10.1016/j.taap.2022.115938. Epub 2022 Feb 24.